ANDA Deficiencies Persist Despite QbR; Reviews to Focus More on Excipients

Despite full adoption of question-based review in the generic drug industry, some of the chemistry and bioequivalence issues QbR was meant to help resolve have persisted, say officials from FDA’s Office of Generic Drugs.